Possible	possible	O	O	O	O
neuroleptic	neuroleptic	O	DISEASE	OTHERS	I
malignant	malignant	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
related	related	O	O	O	O
to	to	O	O	O	O
concomitant	concomitant	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
paroxetine	paroxetine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
alprazolam	alprazolam	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

A	a	O	O	O	O
74-year-old	74-year-old	O	O	O	O
man	man	O	O	O	O
with	with	O	O	O	O
depressive	depressive	O	DISEASE	OTHERS	I
symptoms	symptoms	O	O	OTHERS	I
was	was	O	O	O	O
admitted	admitted	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
psychiatric	psychiatric	O	DISEASE	OTHERS	I
hospital	hospital	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
insomnia	insomnia	O	O	OTHERS	I
,	,	O	O	O	O
loss	loss	O	O	OTHERS	I
of	of	O	O	OTHERS	I
appetite	appetite	O	O	OTHERS	I
,	,	O	O	O	O
exhaustion	exhaustion	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
agitation	agitation	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Medical	medical	O	O	O	O
treatment	treatment	O	O	O	O
was	was	O	O	O	O
initiated	initiated	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
daily	daily	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
20	20	O	O	O	O
mg	mg	O	O	OTHERS	I
paroxetine	paroxetine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
1.2	1.2	O	O	O	O
mg	mg	O	O	OTHERS	I
alprazolam	alprazolam	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

On	on	O	O	O	O
the	the	O	O	O	O
10th	10th	O	O	O	O
day	day	O	O	O	O
of	of	O	O	O	O
paroxetine	paroxetine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
alprazolam	alprazolam	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
exhibited	exhibited	O	O	O	O
marked	marked	O	O	O	O
psychomotor	psychomotor	O	O	OTHERS	I
retardation	retardation	O	O	OTHERS	I
,	,	O	O	O	O
disorientation	disorientation	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
severe	severe	O	O	O	O
muscle	muscle	O	DISEASE	OTHERS	I
rigidity	rigidity	O	DISEASE	OTHERS	I
with	with	O	O	O	O
tremors	tremors	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
fever	fever	O	DISEASE	OTHERS	I
(	(	O	O	O	O
38.2	38.2	O	O	O	O
degrees	degrees	O	O	O	O
C	c	O	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
fluctuating	fluctuating	O	O	O	O
blood	blood	O	O	O	O
pressure	pressure	O	O	O	O
(	(	O	O	O	O
between	between	O	O	O	O
165/90	165/90	O	O	O	O
and	and	O	O	O	O
130/70	130/70	O	O	O	O
mg	mg	O	O	OTHERS	I
mm	mm	O	O	OTHERS	I
Hg	hg	O	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
severe	severe	O	O	O	O
extrapyramidal	extrapyramidal	O	DISEASE	OTHERS	I
symptoms	symptoms	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Laboratory	laboratory	O	O	O	O
tests	tests	O	O	O	O
showed	showed	O	O	O	O
an	an	O	O	O	O
elevation	elevation	O	O	O	O
of	of	O	O	O	O
creatine	creatine	CHEMICALS	O	OTHERS	I
phosphokinase	phosphokinase	O	O	O	O
(	(	O	O	O	O
2218	2218	O	O	O	O
IU/L	iu/l	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
aspartate	aspartate	CHEMICALS	O	OTHERS	I
aminotransferase	aminotransferase	O	O	O	O
(	(	O	O	O	O
134	134	O	O	O	O
IU/L	iu/l	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
alanine	alanine	CHEMICALS	O	OTHERS	I
aminotransferase	aminotransferase	O	O	O	O
(	(	O	O	O	O
78	78	O	O	O	O
IU/L	iu/l	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
BUN	bun	O	O	OTHERS	I
(	(	O	O	O	O
27.9	27.9	O	O	O	O
mg/ml	mg/ml	O	O	O	O
)	)	O	O	O	O
levels	levels	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
received	received	O	O	O	O
bromocriptine	bromocriptine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
diazepam	diazepam	CHEMICALS	O	OTHERS	I
to	to	O	O	O	O
treat	treat	O	O	O	O
his	his	O	O	O	O
symptoms	symptoms	O	O	O	O
.	.	O	O	O	O

7	7	O	O	O	O
days	days	O	O	O	O
later	later	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
fever	fever	O	DISEASE	OTHERS	I
disappeared	disappeared	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
's	's	O	O	O	O
serum	serum	O	O	O	O
CPK	cpk	O	O	O	O
levels	levels	O	O	O	O
were	were	O	O	O	O
normalized	normalized	O	O	O	O
(	(	O	O	O	O
175	175	O	O	O	O
IU/L	iu/l	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
patient	patient	O	O	O	O
presented	presented	O	O	O	O
with	with	O	O	O	O
symptoms	symptoms	O	O	O	O
of	of	O	O	O	O
neuroleptic	neuroleptic	O	DISEASE	OTHERS	I
malignant	malignant	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
(	(	O	O	O	O
NMS	nms	O	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
thus	thus	O	O	O	O
demonstrating	demonstrating	O	O	O	O
that	that	O	O	O	O
NMS-like	nms-like	O	O	O	O
symptoms	symptoms	O	O	O	O
can	can	O	O	O	O
occur	occur	O	O	O	O
after	after	O	O	O	O
combined	combined	O	O	O	O
paroxetine	paroxetine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
alprazolam	alprazolam	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
adverse	adverse	O	O	OTHERS	I
drug	drug	O	O	OTHERS	I
reaction	reaction	O	O	OTHERS	I
score	score	O	O	O	O
obtained	obtained	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
Naranjo	naranjo	O	O	O	O
algorithm	algorithm	O	O	O	O
was	was	O	O	O	O
6	6	O	O	O	O
in	in	O	O	O	O
our	our	O	O	O	O
case	case	O	O	O	O
,	,	O	O	O	O
indicating	indicating	O	O	O	O
a	a	O	O	O	O
probable	probable	O	O	O	O
relationship	relationship	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
patient	patient	O	O	O	O
's	's	O	O	O	O
NMS-like	nms-like	O	O	O	O
adverse	adverse	O	O	O	O
symptoms	symptoms	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
combined	combined	O	O	O	O
treatment	treatment	O	O	O	O
used	used	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
case	case	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
involvement	involvement	O	O	O	O
of	of	O	O	O	O
physiologic	physiologic	O	O	O	O
and	and	O	O	O	O
environmental	environmental	O	O	O	O
aspects	aspects	O	O	O	O
specific	specific	O	O	O	O
to	to	O	O	O	O
this	this	O	O	O	O
patient	patient	O	O	O	O
was	was	O	O	O	O
suspected	suspected	O	O	O	O
.	.	O	O	O	O

Several	several	O	O	O	O
risk	risk	O	O	O	O
factors	factors	O	O	O	O
for	for	O	O	O	O
NMS	nms	O	O	OTHERS	I
should	should	O	O	O	O
be	be	O	O	O	O
noted	noted	O	O	O	O
in	in	O	O	O	O
elderly	elderly	O	O	O	O
depressive	depressive	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
whose	whose	O	O	O	O
symptoms	symptoms	O	O	O	O
often	often	O	O	O	O
include	include	O	O	O	O
dehydration	dehydration	O	DISEASE	OTHERS	I
,	,	O	O	O	O
agitation	agitation	O	DISEASE	OTHERS	I
,	,	O	O	O	O
malnutrition	malnutrition	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
exhaustion	exhaustion	O	O	O	O
.	.	O	O	O	O

Careful	careful	O	O	O	O
therapeutic	therapeutic	O	O	O	O
intervention	intervention	O	O	O	O
is	is	O	O	O	O
necessary	necessary	O	O	O	O
in	in	O	O	O	O
cases	cases	O	O	O	O
involving	involving	O	O	O	O
elderly	elderly	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
suffer	suffer	O	O	O	O
from	from	O	O	O	O
depression	depression	O	DISEASE	OTHERS	I
.	.	O	O	O	O

